FrancophonIA/ELRC3.0 huggingface dataset:
English: The study showed that patients vaccinated with Fluenz Tetra had immune responses against each of the four vaccine virus strains that were comparable to the immune responses stimulated by the Fluenz vaccines.
Danish: Undersøgelsen viste, at patienter, der blev vaccineret med Fluenz Tetra, fik en immunrespons mod hver af de fire virusstammer i vaccinen, og at denne immunrespons var sammenlignelig med den, der blev udløst af Fluenz-vaccinerne.
English: Why is Fluenz Tetra approved?
Danish: Hvorfor er Fluenz Tetra blevet godkendt?
English: What are the risks associated with Fluenz Tetra?
Danish: Hvilke risici er der forbundet med Fluenz Tetra?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Fluenz Tetra have been included in the summary of product characteristics and the package leaflet.
Danish: Der er anført anbefalinger og forholdsregler i produktresuméet og indlægssedlen, som patienter og sundhedspersonale skal følge for at sikre risikofri og effektiv anvendelse af Fluenz Tetra.
English: For the full list of all side effects reported with Fluenz Tetra, see the package leaflet.
Danish: Den fuldstændige liste over indberettede bivirkninger ved Fluenz Tetra fremgår af indlægssedlen.
English: Fluenz Tetra is available as a nasal spray.
Danish: Fluenz Tetra leveres som næsespray.
English: What benefits of Fluenz Tetra have been shown in studies?
Danish: Hvilke fordele viser undersøgelserne, at der er ved Fluenz Tetra?
English: How is Fluenz Tetra used?
Danish: Hvordan anvendes Fluenz Tetra?
English: How does Fluenz Tetra work?
Danish: Hvordan virker Fluenz Tetra?
English: 250 mg Tablet bottle
Danish: 250 mg Tablet
English: Route of Administration
Danish: Oral anvendelse Beholder
English: 22 May 2006 CHMP/477258/2006
Danish: 22. maj 2006 CHMP/477258/2006
English: The company responded to these points on 19 January 2006.
Danish: Firmaet besvarede de rejste spørgsmål den 19. januar 2006.
English: It is registered in the EU since 1996 through Mutual Recognition Procedure and national procedures.
Danish: Lægemidlet har været registreret i EU siden 1996 i henhold til proceduren for gensidig anerkendelse og nationale procedurer.
English: The final opinion was converted into a Decision by the European Commission on 22 May 2006.
Danish: Den endelige udtalelse blev konverteret til en afgørelse truffet af Europa-Kommissionen den 22. maj
English: International Non-Proprietary Name (INN): atorvastatin
Danish: Internationalt fællesnavn (INN): atorvastatin
English: * Notes: The information given in this document and Annexes reflect only the CHMP Opinion dated 23 March
Danish: * Bemærkninger: Oplysningerne i dette dokument og bilagene afspejler udelukkende CHMP's udtalelse af 23. marts
English: The list of product names concerned is given in the Annex I. The scientific conclusions are provided in the Annex II, together with the amended Summary of Product Characteristics in the Annex III.
Danish: Listen over de pågældende lægemiddelnavne fremgår af bilag I. De faglige konklusioner findes i bilag II og det ændrede produktresumé i bilag III.
English: Based on the evaluation of the currently available data and the (Co-)Rapporteurs' assessment reports, the CHMP adopted an opinion on 23 March 2006 recommending the variation of the Marketing Authorisations for the addition of the following new indication:
Danish: I lyset af de aktuelt foreliggende oplysninger, der var blevet fremlagt, og vurderingsrapporterne fra rapportøren/medrapportøren vedtog CPMP den 23. marts 2006 en udtalelse, som anbefalede godkendelse af ændringen af markedsføringstilladelserne med henblik på tilføjelsen af følgende nye indikation:
English: COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CHMP) OPINION FOLLOWING AN ARTICLE 6(12) REFERRAL
Danish: UDVALGET FOR FARMACEUTISKE SPECIALITETER (CHMP) UDTALELSE SOM FØLGE AF EN SAG INDBRAGT I HENHOLD TIL ARTIKEL 6, STK.
English: At the end of the MRP procedure there was a discrepancy between different Member States regarding the wording of the indication that adequately reflects the clinical data submitted by the company, and an official referral for arbitration according to Article 6(12) of Commission Regulation EC No 1084/2003, as amended, was notified by Spain to the CHMP on 1.12.2005.
Danish: Ved afslutningen af den gensidige anerkendelsesprocedure var der blandt forskellige medlemsstater uenighed om ordlyden af indikationen, som er en korrekt gengivelse af de kliniske oplysninger, firmaet har fremlagt, og den 1. december 2005 indgav Spanien i henhold til artikel 6, stk. 12, i Kommissionens forordning (EF) nr. 1084/2003, med ændringer, en sag for CHMP med henblik på voldgift.
English: Sortis and associated names contain atorvastatin, a HMG-CoA-reductase inhibitor (known as statin), which inhibits the synthesis of cholesterol.
Danish: Sortis og tilknyttede navne indeholder atorvastatin, en HMG-CoA-reduktase-hæmmer (kendt som statin), der hæmmer syntesen af kolesterol.
English: The questions identified pertained to: i) the lack of a significant effect in favour of atorvastatin for the composite primary endpoint and several secondary endpoints in the female subgroup, ii) the exclusion of non-diabetic patients at high cardiovascular risk from the proposed indication, iii) the higher cardioprotective effect of atorvastatin when used in combination with particular antihipertensive therapies iv) the extent to which the claimed therapeutic indication could be applied to atorvastatin doses other than those tested in the pivotal trials
Danish: De rejste spørgsmål vedrørte: i) manglen på signifikant virkning til fordel for atorvastatin ved det sammensatte endepunkt og ved adskillige sekundære endepunkter i undergruppen af kvinder, ii) udeladelsen af ikke-diabetikere med høj kardiovaskulær risiko i den foreslåede indikation, iii) den større kardiobeskyttende virkning af atorvastatin, når det anvendes i kombination med bestemte behandlinger af forhøjet blodtryk iv) hvor vidt den terapeutiske indikation, der gøres gældende, kan anvendes på andre doser af atorvastatin end dem, der blev afprøvet i hovedundersøgelserne.
English: This Referral procedure relates to a request for Arbritation concerning a type II variation for a new indication in the “Prevention of cardiovascular events in patients estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors”.
Danish: Denne indbringelsesprocedure vedrører en anmodning om voldgift i forbindelse med en type IIændring af en ny indikation med henblik på “Forebyggelse af kardiovaskulære hændelser hos patienter, som det vurderes har høj risiko for en kardiovaskulær førstegangshændelse, som supplement til afhjælpning af andre risikofaktorer”.
English: “Prevention of cardiovascular events in patients estimated to have a high risk for a first cardiovascular event (see section 5.1), as an adjunct to correction of other risk factors.”
Danish: ”Forebyggelse af kardiovaskulære hændelser hos patienter, som det vurderes har høj risiko for en kardiovaskulær førstegangshændelse, som supplement til afhjælpning af andre risikofaktorer”.
English: Atorvastatin is currently indicated as an adjunct to diet for reduction of elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (Corresponding to Types IIa and IIb of the Fredrickson classification) when response to diet and other nonpharmacological measures is inadequate.
Danish: Atorvastatin er på nuværende tidspunkt indiceret som supplement til diætbehandling med henblik på en reduktion af forhøjet samlet kolesterol og LDL-kolesterol, apolipoprotein B og triglycerider hos patienter med primær hyperkolesterolæmi, herunder familiær hyperkolesterolæmi (heterozygot variant) eller kombineret hyperlipidæmi (svarende til type IIa og IIb i Fredericsons klassifikation), hvor diæt og andre ikke-farmakologiske foranstaltninger er utilstrækkelige.
English: Atorvastatin is also indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.
Danish: Atorvastatin er også indiceret til reduktion af samlet kolesterol og LDL-kolesterol hos patienter med homozygot familiær hyperkolesterolæmi som supplement til anden lipidsænkende behandling (f.eks. LDL-aferese), eller hvis anden behandling ikke er tilgængelig.
English: The arbitration procedure was discussed and initiated by the CHMP at its plenary meeting in December 2005, and a Rapporteur (Dr Eric Abadie) and Co-Rapporteur (Dr Bengt Ljungberg) were appointed.
Danish: Dr. Eric Abadie blev udpeget som rapportør og dr. Bengt Ljungberg som medrapportør.
English: The consecutive treatment should be done at the same time each day.
Danish: Behandlingen bør foretages på samme tidspunkt hver dag.
English: <Batch> <Lot> <BN> number.
Danish: <Batch> <Lot> <BN> nummer.
English: Date of first authorisation: 29 October 2004 Date of last renewal: 23 November 2009
Danish: Dato for første markedsføringstilladelse: 29. oktober 2004 Dato for seneste fornyelse af markedsføringstilladelse: 23. november 2009
English: Wear protective gloves while handling the product.
Danish: Brug beskyttelseshandsker ved håndtering af produktet.
English: The product is mainly excreted in the urine.
Danish: Produktet udskilles hovedsagelig i urinen.
English: Do not use on an empty stomach.
Danish: Må ikke indgives på tom mave.
English: The apparent volume of distribution is 10 l/kg.
Danish: Det tilsyneladende fordelingsvolumen er 10 l/kg.
English: The terminal elimination half-life is 11.7 hours after intravenous administration and 30.84 hours after single oral administration.
Danish: Den terminale eliminationshalveringstid er 11,7 timer efter intravenøs indgift og 30,84 timer efter en enkelt oral indgift.
English: However, in order to make the HALOCUR treatment easier, a simplified dosage scheme is proposed:
Danish: For at gøre HALOCUR-behandlingen lettere foreslås imidlertid følgende forenklede doseringsskema:
English: In case of skin and eye contact wash the exposed area thoroughly with clean water.
Danish: I tilfælde af kontakt med hud eller øjne vaskes det berørte område grundigt med rent vand.
English: The active substance in HALOCUR is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010:
Danish: Det aktive stof i HALOCUR er et tilladt stof som beskrevet i tabel 1 i bilaget til Kommissionens Forordning (EU) Nr. 37/2010:
English: If eye irritation persists, seek medical advice.
Danish: Hvis der fortsat er øjenirritation, skal der søges lægehjælp.
English: HALOCUR should not enter water courses, as this may be dangerous for fish and other aquatic organisms.
Danish: HALOCUR må ikke udledes i vandløb, da dette kan være farligt for fisk og andre organismer i vandet.
English: EXP: month/year Once broached, use within 6 months.
Danish: EXP: måned/år Efter åbning: anvendes indenfor 6 måneder.
English: The concentrations to inhibit 50 % and 90 % of the parasites, in an in vitro test system, are IC50 < 0.1 µg/ml and IC90 of 4.5 µg/ml respectively.
Danish: Den koncentration, der skal til for at hæmme henholdsvis 50% og 90% af parasitterne i et in vitrotestsystem er IC50 < 0,1 µg/ml og IC90 = 4,5 µg/ml.
English: Halofuginone lactate (RU 38788) is a salt whose antiprotozoal properties and efficacy against Cryptosporidium parvum have been demonstrated both in in vitro conditions and in artificial and natural infections.
Danish: Halofuginonlactat (RU 38788) er et salt, hvis antiprotozo-egenskaber og effekt mod Cryptosporidium parvum er blevet påvist både in vitro og ved kunstige og naturlige infektioner.
English: This medicinal product does not require any special storage conditions.
Danish: Dette veterinærlægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen.
English: Liver Kidney Muscle Fat
Danish: Lever Nyre Muskel Fedt
English: Pharmacotherapeutic group: Quinazolinone derivate ATCvet code: QP51AX08
Danish: Farmakoterapeutisk gruppe: Quinazolinonderivat ATCvet-kode: QP51AX08
English: In both cases, the reduction of oocysts excretion has been demonstrated.
Danish: I begge tilfælde er det påvist, at oocyst-udskillesen reduceres.
English: Intervet Productions SA Rue de Lyons F-27460 Igoville France
Danish: Intervet Productions SA Rue de Lyons F-27460 Igoville Frankrig
English: The plasmatic concentrations of halofuginone after repeated oral administrations are comparable to the pharmacokinetic pattern after single oral treatment.
Danish: Plasmakoncentrationerne af halofuginon efter gentagen oral indgift er sammenlignelig med det farmakokinetiske mønster efter en enkelt oral behandling.
English: Once the first calf has been treated, all the forthcoming new-born calves must be systematically treated as long as the risk for diarrhoea due to C. parvum persists.
Danish: Når første kalv er behandlet, skal alle kommende nyfødte kalve behandles på systematisk vis, så længe risikoen for diarré forårsaget af C. parvum foreligger.
English: The bioavailability of the drug in the calf, following single oral administration, is about 80 %.
Danish: Biotilgængeligheden af lægemidlet hos kalve efter en enkelt oral indgift er ca. 80%.
English: To ensure a correct dosage, the use of either a syringe or any appropriate device for oral administration is necessary.
Danish: For at sikre korrekt dosering skal der anvendes en sprøjte eller anden passende anordning til oral administration.
English: The excipients listed in section 6.1 of the SPC are allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required.
Danish: 6.1 i SPC'et er tilladte hjælpestoffer, hvor tabel 1 i bilaget til Kommissionens forordning (EU) Nr. 37/2010 indikerer, at MRL-værdier ikke er påkrævet.
English: Administration should start in the first 24 to 48 hours of age.
Danish: Behandling skal påbegyndes i de første 24 til 48 timer efter fødslen.
English: The animals should receive enough colostrum according to good breeding practice.
Danish: Kalvene skal gives tilstrækkelig kolostrum i overensstemmelse med god landmandspraksis.
English: Manufacturer responsible for batch release: Intervet Productions S.A.
Danish: Fremstiller ansvarlig for batchfrigivelse: Intervet Productions S.A.
English: Unchanged Halofuginone is the major component in the tissues.
Danish: Uomdannet halofuginon er hovedkomponenten i vævene.
English: Symptoms of toxicity include diarrhoea, visible blood in faeces, decline in milk consumption, dehydration, apathy and prostration.
Danish: Symptomer på forgiftning omfatter diarré, synligt blod i afføringen, nedsat mælkeindtag, dehydrering, apati og udmattelse.
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.emea.europa.eu/.
Danish: Yderligere information om dette veterinærlægemiddel er tilgængelig på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu/.
English: For oral use in new born calves after feeding.
Danish: Til oral anvendelse hos nyfødte kalve efter fodring.
English: Do not use in case of diarrhoea established for more than 24 hours and in weak animals.
Danish: Må ikke bruges i tilfælde af diarré, som har varet ved i mere end 24 timer, og til svage dyr.
English: The veterinary medicinal product is a canary yellow oral solution.
Danish: Veterinærlægemidlet er en gul, oral opløsning.
English: Administration should start within 24 hours after the onset of diarrhoea.
Danish: Behandling skal påbegyndes inden for 24 timer efter starten af diarreen.
English: An increase in the level of diarrhoea has been observed in treated animals in very rare cases.
Danish: En forværring af diarreen er i meget sjældne tilfælde set hos behandlede dyr.
English: The active substance, halofuginone, is an antiprotozoal agent of the quinazolinone derivatives group (nitrogenous polyheterocycles).
Danish: Det aktive stof, halofuginon, er et antiprotozomiddel, som tilhører gruppen af quinazolinonderivater (kvælstofholdige polyheterocykliske forbindelser).
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE HDPE container (500 ml and 1000 ml presentations)
Danish: OPLYSNINGER, DER SKAL ANFØRES PÅ DEN INDRE EMBALLAGE HDPE-beholder (pakningsstørrelser a 500 ml og 1000 ml)
English: Benzoic acid (E 210) Tartrazine (E 102) Lactic acid (E 270) Water, purified
Danish: Benzoesyre (E210) Tartrazin (E102) Mælkesyre (E270) Vand, renset
English: Administer after colostrum feeding, or after milk or milk replacer feeding only, using either a syringe or any appropriate device for oral administration.
Danish: Skal indgives efter fodring med kolostrum, mælk eller mælkeerstatning enten med en sprøjte eller anden passende anordning til oral administration.
English: For treatment of anorexic calves, the product should be administered in half a litre of an electrolyte solution.
Danish: Hos kalve uden ædelyst bør produktet indgives sammen med en halv liter elektrolytopløsning.
English: Should clinical signs of overdosing occur the treatment must be stopped immediately and the animal fed unmedicated milk or milk replacer.
Danish: I tilfælde af tegn på overdosering stoppes behandlingen straks og kalven fodres med umedicineret mælk eller mælkeerstatning.
English: New born calves.
Danish: Nyfødte kalve.
English: HALOCUR contains 0.5 mg/ml halofuginone base (as lactate salt).
Danish: HALOCUR indeholder 0,5 mg/ml halofuginon (som laktatsalt).
English: Antiparasitic agents/Agents acting against protozoa
Danish: Antiparasitære lægemidler/midler mod protozoer
English: 35 kg < calves ≤ 45 kg: 8 ml of HALOCUR once a day during 7 consecutive days
Danish: 35 kg < kalve ≤ 45 kg: 8 ml HALOCUR én gang dagligt i 7 på hinanden følgende dage
English: - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Danish: - almindelige (flere end 1, men færre end 10 ud af 100 behandlede dyr) - ikke almindelige (flere end 1, men færre end 10 ud af 1.000 behandlede dyr) - sjældne (flere end 1, men færre end 10 ud af 10.000 behandlede dyr) - meget sjældne (færre end 1 ud af 10.000 behandlede dyr, herunder isolerede rapporter).
English: Avoid skin, eye or mucosal contact with the product.
Danish: Undgå at produktet kommer i kontakt med hud, øjne eller slimhinder.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Danish: Hyppigheden af bivirkninger er defineret som: - meget almindelige (flere end 1 ud af 10 behandlede dyr, der får bivirkninger i løbet af en behandling) - almindelige (flere end 1, men færre end 10 ud af 100 behandlede dyr) - ikke almindelige (flere end 1, men færre end 10 ud af 1.000 behandlede dyr) - sjældne (flere end 1, men færre end 10 ud af 10.000 behandlede dyr) - meget sjældne (færre end 1 ud af 10.000 behandlede dyr, herunder isolerede rapporter).
English: New born calves
Danish: Nyfødte kalve
English: 45 kg < calves < 60 kg: 12 ml of HALOCUR once a day during 7 consecutive days For smaller or higher weights, a precise calculation should be performed (2 ml/10 kg BW).
Danish: 45 kg < kalve < 60 kg: 12 ml HALOCUR én gang dagligt i 7 på hinanden følgende dage Ved lavere eller højere kropsvægt bør der foretages en præcis beregning (2 ml/10 kg kropsvægt).
English: Animal species MRLs
Danish: Restmarkør Dyrearter MRL Målvæv Andre bestemmelser
English: The compound has a cryptosporidiostatic effect on Cryptosporidium parvum.
Danish: Stoffet har en cryptosporidiostatisk effekt på Cryptosporidium parvum.
English: Marketing authorisation holder: Intervet International B.V. Wim de Körverstraat 35
Danish: Indehaver af markedsføringstilladelsen: Intervet International B.V.
English: STATEMENT OF ACTIVE SUBSTANCE
Danish: ANGIVELSE AF AKTIVE STOFFER
English: The dosage is: 100 µg of halofuginone base / kg body weight (BW) / once a day for 7 consecutive days, i.e. 2 ml of HALOCUR / 10 kg BW / once a day for 7 consecutive days.
Danish: Doseringen er: 100 µg halofuginon / kg kropsvægt / 1 gang dagligt i 7 på hinanden følgende dage, svarende til 2 ml HALOCUR / 10 kg kropsvægt / 1 gang dagligt i 7 på hinanden følgende dage.
English: Repetitive contact with the product may lead to skin allergies.
Danish: Særlige forsigtighedsregler for personer, som indgiver lægemidlet til dyr Gentagen kontakt med produktet kan medføre hudallergi.
English: Reduction of diarrhoea due to diagnosed Cryptosporidium parvum.
Danish: Reduktion af diarré forårsaget af diagnosticeret Cryptosporidium parvum.
English: Intervet International B.V. Wim de Körverstraat 35 NL-5831 AN Boxmeer The Netherlands
Danish: Wim de Körverstraat 35 NL-5831 AN Boxmeer Holland
English: Pharmaco-logically active substance
Danish: Farmakologisk aktivt stof
English: PACKAGE LEAFLET: HALOCUR 0.5 mg/ml oral solution for calves
Danish: INDLÆGSSEDDEL: HALOCUR 0,5 mg/ml, oral opløsning til kalve
English: 30 µg/kg 30 µg/kg 10 µg/kg 25 µg/kg
Danish: Halofuginon Halofuginon Kvæg 30 µg/kg 30 µg/kg
English: 500 ml bottle containing 490 ml of oral solution 1000 ml bottle containing 980 ml of oral solution
Danish: 500 ml flaske indeholdende 490 ml oral opløsning 1000 ml flaske indeholdende 980 ml oral opløsning
English: HALOCUR 0.5 mg/ml oral solution for calves
Danish: HALOCUR 0,5 mg/ml, oral opløsning til kalve
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated )
Danish: Hyppigheden af bivirkninger er defineret som: - meget almindelige (flere end 1 ud af 10 behandlede dyr, der får bivirkninger i løbet af en behandling)
English: Halofuginone base (as lactate salt)
Danish: Halofuginon (som laktatsalt)
English: Prevention of diarrhoea due to diagnosed Cryptosporidium parvum, in farms with history of cryptosporidiosis.
Danish: Forebyggelse af diarré forårsaget af diagnosticeret Cryptosporidium parvum i besætninger, der har haft cryptosporidiosis.
English: Oral solution Canary yellow homogenous clear solution.
Danish: Gul, homogen, klar opløsning.
English: (as lactate salt)
Danish: (som laktatsalt)
English: High-density polyethylene portable bottle of 500 ml containing 490 ml of the oral solution.
Danish: Bærbar 500 ml flaske af højdensitetspolyethylen indeholdende 490 ml oral opløsning.
English: High-density polyethylene portable bottle of 1000 ml containing 980 ml of the oral solution.
Danish: Bærbar 1000 ml flaske af højdensitetspolyethylen indeholdende 980 ml oral opløsning.
English: Highdensity polyethylene portable bottle of 1000 ml containing 980 ml of the oral solution.
Danish: Bærbar 1000 ml flaske af HDPE indeholdende 980 ml oral opløsning.
English: Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Danish: Særlige forholdsregler der skal træffes af personer, der administrerer lægemidlet til dyr: Gentagen kontakt med produktet kan medføre hudallergi.
English: Immediate Packaging Content (concentratio n)
Danish: Indhold (Koncentration)
English: 1 blister (7 tablets)
Danish: 7 tabletter 1 blister (7 tabletter)
English: Oral suspension Horses
Danish: Oral suspension Heste
English: Subcutaneous or intravenous use (dogs), subcutaneous use (cats)
Danish: Subkutan eller intravenøs anvendelse (hunde), subkutan anvendelse (katte)
English: Oral suspension Pigs
Danish: Oral suspension Grise
English: Intramuscular use (pigs)
Danish: Subkutan eller intravenøs anvendelse (kvæg), Intramuskulær anvendelse (grise)